theory clinical_88_0
imports Main

begin

typedecl entity
typedecl event

consts
  Patient :: "entity ⇒ bool"
  BRCAMutation :: "entity ⇒ bool"
  Have :: "entity ⇒ entity ⇒ bool"
  Olaparib :: "entity ⇒ bool"
  Talazoparib :: "entity ⇒ bool"
  LicensedPARPInhibitor :: "entity ⇒ bool"
  BRCAMutated :: "entity ⇒ bool"
  HER2Negative :: "entity ⇒ bool"
  AdvancedBC :: "entity ⇒ bool"
  MetastaticBC :: "entity ⇒ bool"
  TreatmentFor :: "entity ⇒ entity ⇒ entity ⇒ bool"
  PARPInhibitor :: "entity ⇒ bool"
  AppropriateFor :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Patient does not have BRCA mutation *)
axiomatization where
  explanation_1: "∀x y. Patient x ∧ BRCAMutation y ⟶ ¬Have x y"

(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)
axiomatization where
  explanation_2: "∀x y z. (Olaparib x ∨ Talazoparib x) ∧ LicensedPARPInhibitor x ∧ Patient y ∧ BRCAMutated y ∧ HER2Negative y ∧ (AdvancedBC z ∨ MetastaticBC z) ⟶ TreatmentFor x y z"

theorem hypothesis:
  assumes asm: "PARPInhibitor x ∧ Patient y"
  (* Hypothesis: PARP inhibitors not appropriate for this patient *)
  shows "∀x y. PARPInhibitor x ∧ Patient y ⟶ ¬AppropriateFor x y"
proof -
  (* From the premise, we have known information about the PARP inhibitor and the patient. *)
  from asm have "PARPInhibitor x ∧ Patient y" by simp
  (* Explanation 1 states that a patient does not have a BRCA mutation. *)
  (* This implies that the patient is not eligible for treatment with licensed PARP inhibitors like Olaparib and Talazoparib, which are for BRCA-mutated patients. *)
  (* Therefore, PARP inhibitors are not appropriate for this patient. *)
  then have "¬AppropriateFor x y" sledgehammer
  then show ?thesis <ATP>
qed

end
